XFOR
XFOR
NASDAQ · Biotechnology

X4 Pharmaceuticals Inc

$3.44
+0.09 (+2.69%)
As of Nov 7, 2:12 AM ET ·
Financial Highlights (FY 2026)
Revenue
67.39M
Net Income
-152,000,683
Gross Margin
83.6%
Profit Margin
-225.6%
Rev Growth
—
D/E Ratio
0.41
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 83.6% 68.8% 43.0% 43.0%
Operating Margin -247.4% -1,281.2% 20.9% 17.6%
Profit Margin -225.6% -1,391.4% 16.3% 17.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 67.39M 38.69M 57.05M 55.03M
Gross Profit 56.34M 26.63M 24.51M 23.64M
Operating Income -166,745,129 -495,763,818 11.90M 9.71M
Net Income -152,000,683 -510,081,137 9.29M 9.37M
Gross Margin 83.6% 68.8% 43.0% 43.0%
Operating Margin -247.4% -1,281.2% 20.9% 17.6%
Profit Margin -225.6% -1,391.4% 16.3% 17.0%
Rev Growth — -5.2% +3.4% -0.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 40.56M 114.10M 127.66M 98.88M
Total Equity 99.05M 33.51M 135.98M 129.32M
D/E Ratio 0.41 3.41 0.94 0.76
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -164,298,079 -479,400,827 17.50M 15.80M
Free Cash Flow — — 7.43M 8.43M